Wells Fargo raised the firm’s price target on Cencora (COR) to $405 from $354 and keeps an Overweight rating on the shares. The firm says the company reported fairly strong Q4 results and introduced attractive FY26 guidance. Core growth in U.S. Healthcare remains outstanding and absent material deceleration would seem to suggest potential for additional positive estimate revisions, Wells adds.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora price target raised to $400 from $350 at TD Cowen
- Cencora price target raised to $371 from $322 at Deutsche Bank
- Cencora price target raised to $415 from $380 at UBS
- Cencora’s Strong Growth Potential and Market Position Justify Buy Rating and Increased Price Target
- Cencora price target raised to $400 from $340 at Evercore ISI